Key Points
- RA Capital Management disclosed a major insider purchase of 6.51 million Artiva Biotherapeutics shares at $11.52 each, totaling about $75 million. The buy lifted its stake by 74.89% to more than 15.2 million shares.
- Artiva Biotherapeutics shares were down 1.2% on the day and opened at $10.50, even after recently trading between a 52-week low of $1.47 and high of $14.53. The company’s market cap is about $259.6 million.
- The company recently reported a quarterly EPS loss of $0.95, missing analyst expectations, but Wall Street sentiment has turned more bullish with multiple firms raising price targets to around $40-$41 and maintaining buy-style ratings.
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) Director Ra Capital Management, L.P. bought 6,510,416 shares of Artiva Biotherapeutics stock in a transaction dated Monday, May 11th. The shares were bought at an average cost of $11.52 per share, with a total value of $74,999,992.32. Following the completion of the acquisition, the director owned 15,203,995 shares of the company's stock, valued at $175,150,022.40. The trade was a 74.89% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Artiva Biotherapeutics Stock Down 1.2%
Shares of NASDAQ ARTV opened at $10.50 on Thursday. Artiva Biotherapeutics, Inc. has a 12 month low of $1.47 and a 12 month high of $14.53. The company has a market cap of $259.56 million, a price-to-earnings ratio of -2.97 and a beta of 2.86. The business has a fifty day simple moving average of $8.00 and a 200-day simple moving average of $5.52.
Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last announced its earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). As a group, sell-side analysts expect that Artiva Biotherapeutics, Inc. will post -2.8 EPS for the current fiscal year.
Trending Headlines about Artiva Biotherapeutics
Here are the key news stories impacting Artiva Biotherapeutics this week:
- Positive Sentiment: Ra Capital Management disclosed a purchase of 6.51 million shares at $11.52 each, a roughly $75 million insider buy that materially increased its stake in Artiva Biotherapeutics. SEC Form 4 filing
- Positive Sentiment: Needham & Company raised its price target on Artiva Biotherapeutics to $41 from $18 and kept a buy rating, implying substantial upside from current levels. Benzinga report
- Positive Sentiment: HC Wainwright reiterated a buy rating and $35 price target while raising several earnings estimates for 2026 and beyond, suggesting improving expectations for the company’s long-term earnings path.
- Positive Sentiment: Additional analyst updates from Cantor Fitzgerald and Wedbush were also described as positive, reinforcing the broader bullish sentiment around ARTV.
- Neutral Sentiment: Some HC Wainwright estimates were mixed, with certain long-term EPS forecasts lowered even as nearer-term projections improved, so the analyst picture is not uniformly optimistic.
Institutional Trading of Artiva Biotherapeutics
Hedge funds have recently added to or reduced their stakes in the business. Prelude Capital Management LLC bought a new stake in shares of Artiva Biotherapeutics in the 3rd quarter worth approximately $41,000. Bank of America Corp DE lifted its position in shares of Artiva Biotherapeutics by 225.8% in the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company's stock worth $46,000 after acquiring an additional 11,190 shares during the period. Bridgeway Capital Management LLC bought a new stake in shares of Artiva Biotherapeutics in the 2nd quarter worth approximately $53,000. Qube Research & Technologies Ltd bought a new stake in shares of Artiva Biotherapeutics in the 2nd quarter worth approximately $58,000. Finally, Jane Street Group LLC bought a new stake in shares of Artiva Biotherapeutics in the 2nd quarter worth approximately $67,000.
Analyst Ratings Changes
Several equities research analysts recently issued reports on ARTV shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. Cantor Fitzgerald upped their target price on Artiva Biotherapeutics from $10.00 to $40.00 and gave the stock an "overweight" rating in a research report on Monday. Wedbush increased their price objective on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an "outperform" rating in a report on Monday. Needham & Company LLC increased their price objective on Artiva Biotherapeutics from $18.00 to $41.00 and gave the company a "buy" rating in a report on Tuesday. Finally, Wall Street Zen raised Artiva Biotherapeutics from a "sell" rating to a "hold" rating in a report on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $39.00.
Read Our Latest Stock Analysis on Artiva Biotherapeutics
About Artiva Biotherapeutics
(
Get Free Report)
Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company's proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.
Artiva's pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
